Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air

This study evaluates the change in the composition of Volatil Organic Compounds (VOC) in patients treated by monoclonal antibody for severe asthma.

  • 3 views
  • 21 Feb, 2021
  • 2 locations
Concurrent WOKVAC Vaccination Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

This phase II trial studies the immunologic response and side effects of using the WOKVAC vaccine in combination with chemotherapy and HER2-targeted monoclonal antibody therapy before surgery in

  • 0 views
  • 09 Jul, 2021
  • 1 location
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rituximab is a type of antibody therapy, which targets and attaches to

  • 0 views
  • 24 May, 2021
  • 1 location
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

This is a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181 administered alone and in combination with anti-PD-(L)1 therapy in adult patients with locally advanced or metastatic solid tumors. The study is divided into …

targeted therapy
solid neoplasm
solid tumour
measurable disease
lymphoma
  • 2 views
  • 30 Jan, 2021
  • 3 locations
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

+Camrelizumab in patients with Hodgkin Lymphoma who were confirmed resistant to Anti-PD-1 antibody therapy.

lymphoma
classical hodgkin lymphoma
refractory hodgkin lymphoma
cell transplantation
  • 0 views
  • 24 Jan, 2021
  • 1 location
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer

effect and safety of watch and wait in patients with dMMR/MSI-H distal RC accessed pCR after PD-1 monoclonal antibody therapy.

transrectal ultrasound
metastasis
chemoradiotherapy
adenocarcinoma
rectal surgery
  • 0 views
  • 23 May, 2021
  • 1 location
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

rituximab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) together with monoclonal antibody therapy may kill more cancer cells.

rituximab
cyclophosphamide
immunodeficiency
prednisone
monoclonal antibody therapy
  • 5 views
  • 24 Jan, 2021
  • 2 locations
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced Recurrent or Refractory Hepatic Metastatic Cancer

. Giving combination chemotherapy and monoclonal antibody therapy while using the NovoTTF-100L(P) system may kill more tumor cells.

metastasis
fluorouracil
palliative radiation therapy
bevacizumab
temsirolimus
  • 0 views
  • 25 Jan, 2021
CC-486 Lenalidomide and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Obinutuzumab is a type of antibody therapy that targets and attaches to the CD20 proteins found on follicular

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Multi-center Non-randomized Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin Vindesine Dacarbazine) Under the Guidance of PET/CT

(PET/CT2): CR patients: continue to receive PD-1 antibody monotherapy, and then receive 4 courses of PD-1 antibody therapy; PR patients: sequential 4 courses of PD-1 antibody + AVD combined

  • 0 views
  • 18 Apr, 2021
  • 1 location